<DOC>
	<DOCNO>NCT00563147</DOCNO>
	<brief_summary>The purpose study test safety tolerability tivozanib ( AV-951 ) Torisel™ give combination renal cell cancer . The study also assess effect combination tivozanib ( AV-951 ) Torisel™ tumor . Tivozanib ( AV-951 ) VEGF-receptor tyrosine kinase inhibitor , may stop growth tumor cell block blood flow tumor . Temsirolimus mTOR inhibitor approve treatment advance renal cell carcinoma .</brief_summary>
	<brief_title>A Phase 1b , Open-Label , Dose-Finding Study Evaluate Safety Tivozanib ( AV-951 ) Combination With Temsirolimus Subjects With Metastatic Renal Cell Carcinoma</brief_title>
	<detailed_description>This Phase 1b , open-label , dose-finding study tivozanib ( AV-951 ) combination temsirolimus include approximately 36 subject metastatic renal cell carcinoma ( mRCC ) . This study design evaluate safety , tolerability , dose-limiting toxicity ( DLT ) , maximum tolerate dose ( MTD ) , pharmacokinetic , pharmacogenomic , antineoplastic activity tivozanib ( AV-951 ) administer combination temsirolimus . Tivozanib ( AV-951 ) administer daily 3 week begin Day 1 Cycle 1 , follow 1 week ( 1 cycle = 4 week ) . Temsirolimus administer intravenously weekly start Day 8 Cycle 1 .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>≥ 18yearold male female Histologically confirm renal cell carcinoma clear cell component Documented progressive disease Measurable disease RECIST criteria No 1 prior VEGF receptor target therapy ; prior treatment temsirolimus drug target mTOR pathway Karnofsky performance status &gt; 70 % ; life expectancy ≥ 3 month Ability give write informed consent Known hypersensitivity temsirolimus metabolite ( include sirolimus ) , polysorbate 80 , component temsirolimus formulation Primary CNS malignancy ; active CNS metastases Hematologic malignancy ( include leukemia form , lymphoma , multiple myeloma ) Any follow hematologic abnormality : Hemoglobin &lt; 9.0 g/dL ANC &lt; 1500 per mm3 Platelet count &lt; 100,000 per mm3 Any follow serum chemistry abnormality : Fasting serum cholesterol &gt; 350 mg/dL Fasting triglycerides &gt; 400 mg/dL Total bilirubin &gt; 1.5 × ULN AST ALT &gt; 2.5 × ULN ( &gt; 5 x ULN subject liver metastasis ) Serum albumin &lt; 3.0 g/dL Creatine &gt; 1.5 × ULN ( calculate CLCR &lt; 50 mL/min/1.73 m2 ) Proteinuria &gt; 2.5 g/24 hour 3+ urine dipstick Significant cardiovascular disease , include : Active clinically symptomatic leave ventricular failure Active hypertension ( diastolic blood pressure &gt; 100 mmHg ) . Subjects history hypertension must stable dos antihypertensive drug ≥ 4 week Uncontrolled hypertension : Blood pressure &gt; 140/90 mmHg 2 antihypertensive medication Myocardial infarction within 3 month prior administration first dose study drug Subjects delay heal wound , ulcer , and/or bone fracture Pulmonary hypertension pneumonitis Serious/active infection ; infection require parenteral antibiotic Inadequate recovery prior surgical procedure ; major surgical procedure within 6 week prior study entry Uncontrolled psychiatric disorder , alter mental status precluding inform consent necessary test Inability comply protocol requirement Ongoing hemoptysis history clinically significant bleed Cerebrovascular accident within 12 month study entry , peripheral vascular disease claudication walk less 1 block Deep venous thrombosis pulmonary embolus within 6 month study entry and/or ongoing need fulldose oral parenteral anticoagulation Subjects `` currently active '' second primary malignancy nonmelanoma skin cancer . Subjects consider `` currently active '' malignancy complete anticancer therapy consider physician &lt; 30 % risk relapse . Pregnant lactating woman Known concomitant genetic acquire immune suppression disease HIV Prohibited medication : VEGF receptor ( VEGFR ) target therapy within 4 week prior study Other signal transduction inhibitor , monoclonal antibody , etc. , within 4 week prior study Immunotherapy biological response modifier within 4 week prior study Systemic hormonal therapy within 4 week prior study , exception : Hormonal therapy appetite stimulation contraception Nasal , ophthalmic , topical glucocorticoid preparation Oral replacement therapy adrenal insufficiency Lowdose maintenance steroid therapy condition Herbal preparations/supplements ( except daily multivitamin/mineral supplement contain herbal component ) within 2 week prior study Any experimental therapy 4 week prior study Radiotherapy : At least 2 week since prior local radiation therapy ( ie , involve &lt; 25 % bone marrow ) time study entry At least 4 week since prior radiation therapy involve ≥ 25 % bone marrow Treatment CYP3A4 inducer inhibitor study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>tivozanib</keyword>
	<keyword>AV-951</keyword>
</DOC>